Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beta-lactam + macrolide is a combination antibiotic therapy commonly used for treating community-acquired pneumonia (CAP). This regimen combines a beta-lactam antibiotic (such as penicillins or cephalosporins) with a macrolide antibiotic (such as azithromycin, erythromycin, or clarithromycin). The combination provides broader spectrum coverage against both typical and atypical pathogens. Macrolides contribute additional immunomodulatory properties that reduce inflammatory responses and may improve clinical outcomes beyond their antimicrobial effects. This combination has shown particular benefit in patients with pneumococcal pneumonia and those with high inflammatory markers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta-lactam + macrolide.